Inhibitors of alprazolam metabolism in vitro: effect of serotonin‐ reuptake‐inhibitor antidepressants, ketoconazole and quinidine.

British Journal of Clinical Pharmacology

Volumn 38, Issue 1, 1994, Pages 23-31

  von Moltke, LL ^a   Greenblatt, DJ ^a   Cotreau‐Bibbo, MM ^a   Harmatz, JS ^a   Shader, RI ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CYTOCHROME P450 ISOENZYME; FLUOXETINE; KETOCONAZOLE; NORFLUOXETINE; NORSERTRALINE; PHENACETIN; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MALE; MONKEY; MOUSE; NONHUMAN; RAT; XENOBIOTIC METABOLISM;

ADULT; AGED; ALPRAZOLAM; ANIMAL; ANTIDEPRESSIVE AGENTS; BIOTRANSFORMATION; COMPARATIVE STUDY; FEMALE; HUMAN; HYDROXYLATION; KETOCONAZOLE; MACACA FASCICULARIS; MALE; MICE; MICROSOMES, LIVER; MIDDLE AGE; QUINIDINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; SPECIES SPECIFICITY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028279667     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1994.tb04317.x     Document Type: Article

References (56)

1. Alprazolam: A review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression
2. Alprazolam: Pharmacokinetics, clinical efficacy, and mechanism of action
3. What are pharmacists dispensing most often
4. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
5. Fluoxetine: A serotonin‐specific, second‐generation antidepressant
6. Sertraline
7. Fluoxetine drug‐drug interactions
8. Inhibition by fluoxetine of cytochrome P450 2D6 activity
9. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6—the source of the sparteine/debrisoquine oxidation polymorphism
10. Inhibitors of imipramine metabolism by human liver microsomes
11. Inhibition of desmethylimipramine 2‐hydroxylation by drugs in human liver microsomes
12. The effect of selective serotonin re‐uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes
13. 14C‐alprazolam, a new anxiolytic‐antidepressant, in man
14. Clinical pharmacokinetics of alprazolam: therapeutic implications
15. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications
16. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine
17. Fluoxetine impairs clearance of alprazolam but not of clonazepam
18. Clinical pharmacokinetics of selective serotonin reuptake inhibitors
19. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam
20. Terfenadine‐ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences
21. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro
22. Progesterone metabolism in hepatic microsomes
23. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes
24. Inhibition of desipramine hydroxylation in vitro by serotonin‐reuptake‐inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo
25. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes
26. Inhibition of acetaminophen and lorazepam glucuronidation in vitro by probenecid
27. New high‐performance liquid chromatographic method for the determination of alprazolam and its metabolites in serum: Instability of 4‐hydroxyalprazolam
28. Kinetics of low dose intravenous antipyrine: use of liquid chromatography
29. Glucuronidation of 3′‐azido‐3′‐deoxythymidine catalyzed by human liver UDP‐glucuronosyltransferase: significance of nucleoside hydrophobicity and inhibition by xenobiotics
30. The rational selection of drug interaction studies: implications of recent advances in drug metabolism
31. The relationship of alprazolam dose to steady‐state plasma concentrations
32. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects
33. 14C] alprazolam in rats
34. Plasma alprazolam concentrations: relation to efficacy and side effects in the treatment of panic disorder
35. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
36. Triazolam hydroxylation in vitro: species differences and metabolic inhibition (abstract)
37. The pharmacokinetics of ketoconazole after chronic administration in adults
38. Oxidation of quinidine by human liver cytochrome P‐450
39. The role of individual human cytochromes P450 in drug metabolism and clinical response
40. In vitro approaches can predict human drug metabolism
41. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects
42. In vitro systems for prediction of rates of drug clearance and drug interactions
43. Human drug metabolism in vitro
44. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics
45. P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease
46. Human cytochrome P‐450 enzymes
47. Human cytochromes P450: problems and prospects
48. Understanding consequences of concurrent therapies
49. Role of cytochromes P450 in drug metabolism and hepatotoxicity
50. The human hepatic cytochromes P450 involved in drug metabolism
51. Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats
52. The metabolism of phenytoin by isolated hepatocytes and hepatic microsomes from male rats
53. Physical partitioning as the major source of metoprolol uptake by hepatic microsomes
54. Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver
55. Distribution of trimipramine and its major metabolites in a fatal overdose case